Fredun Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 7 May 2024, inter alia, have recommended the final dividend of Rs 0.7 per equity Share (i.e. 7%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 30.08% to Rs 5.06 crore in the quarter ended March 2024 as against Rs 3.89 crore during the previous quarter ended March 2023. Sales rose 47.01% to Rs 117.21 crore in the quarter ended March 2024 as against Rs 79.73 crore during the previous quarter ended March 2023.For the full year,net profit rose 44.50% to Rs 15.62 crore in the year ended March 2024 as against Rs 10.81 crore during the previous year ended March 2023. Sales rose 26.33% to Rs 346.58 crore in the year ended March 2024 as against Rs 274.34 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales117.2179.73 47 346.58274.34 26 OPM %9.5315.38 -11.2210.79 - PBDT6.808.71 -22 25.2520.32 24 PBT5.848.01 -27 21.4517.51 23 NP5.063.89 30 15.6210.81 44 Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 May 2024.Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 21.97% to Rs 4.22 crore in the quarter ended December 2023 as against Rs 3.46 crore during the previous quarter ended December 2022. Sales rose 11.59% to Rs 86.65 crore in the quarter ended December 2023 as against Rs 77.65 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales86.6577.65 12 OPM %12.149.41 - PBDT6.755.36 26 PBT5.764.62 25 NP4.223.46 22 Powered by Capital Market - Live News

Fredun Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 18 January 2024.Powered by Capital Market - Live News